SCHEMBL6132283

SCHEMBL6132283

CC1CCC(N2CCN(c3ccc(C(=O)NN)cc3)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ITGB3 P05106 1/20 0.52
ITGA2B P08514 1/20 0.52
ALOX15 P16050 1/20 0.51
USP2 O75604 1/20 0.50
HDAC3 O15379 5/20 0.46
HDAC8 Q9BY41 5/20 0.46
MBTD1 Q05BQ5 1/20 0.45
TP53BP1 Q12888 1/20 0.45
L3MBTL4 Q8NA19 1/20 0.45
L3MBTL3 Q96JM7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM4E B2RXH2 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SMYD3 Q9H7B4 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
AOC2 O75106 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134717 0.88 ITGB3 (0.52) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6134192 0.86 ITGB3 (0.51) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6135305 0.85 HRH3 (0.51) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6132405 0.84 MEN1 (0.52) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6134863 0.83 KMT2A (0.51) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6132502 0.83 KDM4E (0.51) MEN1KMT2AITGB3ITGA2BALOX15
SCHEMBL6132270 0.82 RAB9A (0.53) KDM4ESMN1; SMN2
SCHEMBL6132274 0.82 RAB9A (0.53) KDM4ESMN1; SMN2
SCHEMBL3085835 0.81 AOC2 (0.59) MEN1KMT2AITGB3ITGA2BUSP2
SCHEMBL6134910 0.80 USP2 (0.67) MEN1KMT2AITGB3ITGA2BALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
CN-1425026-A Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2003-06-18 CN disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 MEN1 1517/4885KMT2A 4695/4885ITGB3 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.